JPWO2020216697A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020216697A5 JPWO2020216697A5 JP2021562979A JP2021562979A JPWO2020216697A5 JP WO2020216697 A5 JPWO2020216697 A5 JP WO2020216697A5 JP 2021562979 A JP2021562979 A JP 2021562979A JP 2021562979 A JP2021562979 A JP 2021562979A JP WO2020216697 A5 JPWO2020216697 A5 JP WO2020216697A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- amino acid
- acid sequence
- antibody fragment
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962837214P | 2019-04-23 | 2019-04-23 | |
| US62/837,214 | 2019-04-23 | ||
| PCT/EP2020/060955 WO2020216697A1 (en) | 2019-04-23 | 2020-04-20 | Cd73 blocking antibodies |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2022530404A JP2022530404A (ja) | 2022-06-29 |
| JP2022530404A5 JP2022530404A5 (https=) | 2023-04-25 |
| JPWO2020216697A5 true JPWO2020216697A5 (https=) | 2023-04-25 |
| JP7530913B2 JP7530913B2 (ja) | 2024-08-08 |
Family
ID=70456747
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021562979A Active JP7530913B2 (ja) | 2019-04-23 | 2020-04-20 | Ｃｄ７３遮断抗体 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US12528876B2 (https=) |
| EP (1) | EP3959239A1 (https=) |
| JP (1) | JP7530913B2 (https=) |
| KR (1) | KR20220002959A (https=) |
| CN (1) | CN113784981B (https=) |
| AU (1) | AU2020260693A1 (https=) |
| BR (1) | BR112021021224A2 (https=) |
| CA (1) | CA3136698A1 (https=) |
| IL (1) | IL286997A (https=) |
| MX (1) | MX2021012769A (https=) |
| SG (1) | SG11202111106WA (https=) |
| TW (1) | TWI834867B (https=) |
| WO (1) | WO2020216697A1 (https=) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL250579B2 (en) | 2014-10-10 | 2023-05-01 | Innate Pharma | blocking cd73 |
| WO2019068907A1 (en) * | 2017-10-06 | 2019-04-11 | Innate Pharma | RESTORATION OF T CELL ACTIVITY BY AXIS CD39 / CD73 |
| WO2021138467A1 (en) | 2020-01-03 | 2021-07-08 | Incyte Corporation | Anti-cd73 antibodies and uses thereof |
| CA3166536A1 (en) | 2020-01-03 | 2021-07-08 | Incyte Corporation | Cd73 inhibitor and a2a/a2b adenosine receptor inhibitor combination therapy |
| WO2022033978A2 (en) * | 2020-08-13 | 2022-02-17 | Innate Pharma | Cancer treatment methods using anti-cd73 antibodies |
| CN119173276A (zh) | 2022-04-13 | 2024-12-20 | 吉利德科学公司 | 用于治疗表达Trop-2的癌症的组合疗法 |
| WO2024040194A1 (en) | 2022-08-17 | 2024-02-22 | Capstan Therapeutics, Inc. | Conditioning for in vivo immune cell engineering |
| US12311033B2 (en) | 2023-05-31 | 2025-05-27 | Capstan Therapeutics, Inc. | Lipid nanoparticle formulations and compositions |
| WO2025076113A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Ionizable cationic lipids with conserved spacing and lipid nanoparticles |
| WO2025076127A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
| WO2025137640A1 (en) | 2023-12-22 | 2025-06-26 | Gilead Sciences, Inc. | Azaspiro wrn inhibitors |
| WO2025179294A2 (en) | 2024-02-22 | 2025-08-28 | Capstan Therapeutics, Inc. | Immune engineering amplification |
| WO2025217452A1 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
| WO2025217454A2 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Ionizable cationic lipids and lipid nanoparticles |
| WO2025233264A1 (en) | 2024-05-07 | 2025-11-13 | Innate Pharma | Use of cd73 blocking agents in combination with anti-cd20 x cd3 t cell engagers |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5567610A (en) | 1986-09-04 | 1996-10-22 | Bioinvent International Ab | Method of producing human monoclonal antibodies and kit therefor |
| US5229275A (en) | 1990-04-26 | 1993-07-20 | Akzo N.V. | In-vitro method for producing antigen-specific human monoclonal antibodies |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| DE60334453D1 (de) | 2002-05-30 | 2010-11-18 | Macrogenics Inc | Cd16a bindungsproteine und verwendung zur behandlung von immunkrankheiten |
| RU2494107C2 (ru) | 2005-05-09 | 2013-09-27 | Оно Фармасьютикал Ко., Лтд. | Моноклональные антитела человека к белку программируемой смерти 1 (pd-1) и способы лечения рака с использованием анти-pd-1-антител самостоятельно или в комбинации с другими иммунотерапевтическими средствами |
| CN104356236B (zh) | 2005-07-01 | 2020-07-03 | E.R.施贵宝&圣斯有限责任公司 | 抗程序性死亡配体1(pd-l1)的人单克隆抗体 |
| US20090028857A1 (en) | 2007-07-23 | 2009-01-29 | Cell Genesys, Inc. | Pd-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof |
| PT2242773T (pt) | 2008-02-11 | 2017-09-15 | Cure Tech Ltd | Anticorpos monoclonais para o tratamento de tumores |
| WO2009114335A2 (en) | 2008-03-12 | 2009-09-17 | Merck & Co., Inc. | Pd-1 binding proteins |
| AU2009333580B2 (en) | 2008-12-09 | 2016-07-07 | Genentech, Inc. | Anti-PD-L1 antibodies and their use to enhance T-cell function |
| NZ628923A (en) | 2009-11-24 | 2016-02-26 | Medimmune Ltd | Targeted binding agents against b7-h1 |
| ES2751549T3 (es) | 2009-11-30 | 2020-04-01 | Janssen Biotech Inc | Mutantes de anticuerpos Fc con funciones efectoras ablacionadas |
| AR083847A1 (es) | 2010-11-15 | 2013-03-27 | Novartis Ag | Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40 |
| KR101970025B1 (ko) | 2011-04-20 | 2019-04-17 | 메디뮨 엘엘씨 | Ｂ7-ｈ1 및 ｐｄ-1과 결합하는 항체 및 다른 분자들 |
| JP6238459B2 (ja) | 2011-08-01 | 2017-11-29 | ジェネンテック， インコーポレイテッド | Ｐｄ−１軸結合アンタゴニストとｍｅｋ阻害剤を使用する癌の治療方法 |
| MY184154A (en) | 2013-12-12 | 2021-03-23 | Shanghai hengrui pharmaceutical co ltd | Pd-1 antibody, antigen-binding fragment thereof, and medical application thereof |
| IL250579B2 (en) * | 2014-10-10 | 2023-05-01 | Innate Pharma | blocking cd73 |
| US20180030144A1 (en) | 2014-10-10 | 2018-02-01 | Innate Pharma | Cd73 blockade |
| MY189836A (en) * | 2014-11-21 | 2022-03-11 | Bristol Myers Squibb Co | Antibodies against cd73 and uses thereof |
| AU2016299166B2 (en) | 2015-07-24 | 2022-03-31 | Innate Pharma | Methods for detecting tissue infiltrating NK cells |
| US11130817B2 (en) | 2015-10-12 | 2021-09-28 | Innate Pharma | CD73 blocking agents |
| EP3380519A1 (en) | 2015-11-23 | 2018-10-03 | Innate Pharma | Cd39 vascular isoform targeting agents |
| WO2017100670A1 (en) | 2015-12-09 | 2017-06-15 | Corvus Pharmaceuticals, Inc. | Humanized anti-cd73 antibodies |
| WO2017112803A1 (en) * | 2015-12-22 | 2017-06-29 | Abbvie Stemcentrx Llc | Novel anti-mmp16 antibodies and methods of use |
| US20190071514A1 (en) | 2016-03-14 | 2019-03-07 | Innate Pharma | Anti-cd39 antibodies |
| US20200023071A1 (en) | 2017-02-06 | 2020-01-23 | Innate Pharma | Immunomodulatory antibody drug conjugates binding to a human mica polypeptide |
| CN110382544B (zh) | 2017-03-16 | 2023-12-22 | 先天制药公司 | 用于治疗癌症的组合物和方法 |
| WO2019068907A1 (en) | 2017-10-06 | 2019-04-11 | Innate Pharma | RESTORATION OF T CELL ACTIVITY BY AXIS CD39 / CD73 |
| SG11202002195YA (en) | 2017-11-15 | 2020-04-29 | Innate Pharma | Potentiating the effect of atp release |
| EP3569618A1 (en) * | 2018-05-19 | 2019-11-20 | Boehringer Ingelheim International GmbH | Antagonizing cd73 antibody |
| MX2020012107A (es) * | 2018-06-18 | 2021-01-29 | Innate Pharma | Composiciones y procedimientos para el tratamiento del cancer. |
| WO2022033978A2 (en) | 2020-08-13 | 2022-02-17 | Innate Pharma | Cancer treatment methods using anti-cd73 antibodies |
-
2020
- 2020-04-20 SG SG11202111106WA patent/SG11202111106WA/en unknown
- 2020-04-20 AU AU2020260693A patent/AU2020260693A1/en active Pending
- 2020-04-20 BR BR112021021224A patent/BR112021021224A2/pt unknown
- 2020-04-20 WO PCT/EP2020/060955 patent/WO2020216697A1/en not_active Ceased
- 2020-04-20 KR KR1020217036983A patent/KR20220002959A/ko active Pending
- 2020-04-20 MX MX2021012769A patent/MX2021012769A/es unknown
- 2020-04-20 JP JP2021562979A patent/JP7530913B2/ja active Active
- 2020-04-20 CN CN202080030003.3A patent/CN113784981B/zh active Active
- 2020-04-20 EP EP20721175.6A patent/EP3959239A1/en active Pending
- 2020-04-20 CA CA3136698A patent/CA3136698A1/en active Pending
- 2020-04-23 TW TW109113576A patent/TWI834867B/zh active
-
2021
- 2021-10-05 IL IL286997A patent/IL286997A/en unknown
- 2021-10-22 US US17/451,835 patent/US12528876B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2020216697A5 (https=) | ||
| IL302078A (en) | Anti-CCR8 monoclonal antibodies and their uses | |
| JP2022093564A5 (https=) | ||
| ES2387809T3 (es) | Anticuerpo frente al receptor del factor de crecimiento epidérmico humano | |
| JP2023061927A5 (https=) | ||
| JP2022079549A5 (https=) | ||
| JP2020515508A5 (https=) | ||
| JP2022513420A5 (https=) | ||
| JP2010536384A5 (https=) | ||
| JPWO2020122034A5 (https=) | ||
| JP2024102055A5 (https=) | ||
| JP2010535713A5 (https=) | ||
| JP2021531254A5 (https=) | ||
| JP2020526478A5 (https=) | ||
| JP2020500834A5 (https=) | ||
| JP2017500018A5 (https=) | ||
| JP2020513809A5 (https=) | ||
| JP2020502271A5 (https=) | ||
| ME02371B (me) | Sastojci i postupci za dijagnstikovanje i tretman raka | |
| JP2020521478A5 (https=) | ||
| JP2017113019A5 (https=) | ||
| JP2021523170A5 (https=) | ||
| JP2025032102A5 (https=) | ||
| JP2020517239A5 (https=) | ||
| JP2018512124A5 (https=) |